YugaCell

Executive Summary

YugaCell is a Swiss private company headquartered in Lausanne, founded in 2017, that provides specialized solutions in multiomics, single-cell technologies, bioinformatics, immune repertoire profiling, and AI/ML/statistics. The company serves academia, biotech, and pharma clients by tackling challenging R&D projects, positioning itself as a contract research organization (CRO) with a focus on cutting-edge cell therapy and regenerative medicine applications. Despite a lack of disclosed funding rounds or valuation, YugaCell leverages its expertise in data-intensive fields to support drug discovery and biomarker development. The company's service-based model offers a recurring revenue stream, though it faces competition from larger CROs and tech platforms. YugaCell's location in Switzerland provides access to a robust life sciences ecosystem, but its modest online presence and zero profile views suggest limited market visibility. The company's growth potential hinges on its ability to differentiate through AI/ML integration and secure partnerships with major pharma players. With no commercial products or FDA approvals, YugaCell remains an early-stage service provider concentrating on research enablement rather than proprietary therapies. Its conviction score of 50 reflects a balanced view of its technical capabilities versus market traction.

Upcoming Catalysts (preview)

• Q4 2026Launch of an Integrated AI-Driven Multiomics Platform60% success
• Q2 2026Strategic Partnership with a Top-20 Pharma Company40% success